Intelligence Feed event · Equity · 2026-09-18

    Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs

    Question

    Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs

    Direct answer

    Eli Lilly recorded $27.7 billion in H1 2026 sales across its core GLP-1 injectable portfolio, comprising Mounjaro and Zepbound. The franchise remains the central cash generator for the pharmaceutical company. Commercial rollout of oral obesity pill Foundayo gained momentum after securing formulary coverage across major US pharmacy benefit managers. Non-incretin therapies expanded 121% year-over-year in Q2 2026, moderating concentration risk despite a 7% monthly share pullback.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-18
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs”, revision 1, evidence through 2026-09-18. https://marketontology.com/market-events/2026-09-18/eli-lilly-h1-glp-1-sales-reach-27-7b-as-oral-obesity-pill-foundayo-secures-pbms-c511b0

    EQUITY
    Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs
    Eli Lilly recorded $27.7 billion in H1 2026 sales across its core GLP-1 injectable portfolio, comprising Mounjaro and Zepbound. The franchise remains the central cash generator for the pharmaceutical company. Commercial rollout of oral obesity pill Foundayo gained momentum after securing formulary coverage across major US pharmacy benefit managers. Non-incretin therapies expanded 121% year-over-year in Q2 2026, moderating concentration risk despite a 7% monthly share pullback.
    LLYNVO
    Impact
    67
    SEP 18
    SIG
    85%
    LLYNVO
    Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs
    Eli Lilly recorded $27.7 billion in H1 2026 sales across its core GLP-1 injectable portfolio, comprising Mounjaro and Zepbound. The franchise remains the central cash generator for the pharmaceutical company. Commercial rollout of oral obesity pill Foundayo gained momentum after securing formulary coverage across major US pharmacy benefit managers. Non-incretin therapies expanded 121% year-over-year in Q2 2026, moderating concentration risk despite a 7% monthly share pullback.
    → Formulary access for oral obesity candidate Foundayo across major PBMs expands commercial volume, supporting Lilly's $27.7 billion H1 GLP-1 revenue base.
    Impact
    Eli Lilly recorded $27.7 billion in H1 2026 sales across its core GLP-1 injectable portfolio, comprising Mounjaro and Zepbound. The franchise remains the central cash generator for the pharmaceutical company. Commercial rollout of oral obesity pill Foundayo gained momentum after securing formulary coverage across major US pharmacy benefit managers. Non-incretin therapies expanded 121% year-over-year in Q2 2026, moderating concentration risk despite a 7% monthly share pullback.
    Affected
    LLYNVO
    Transmission
    Formulary access for oral obesity candidate Foundayo across major PBMs expands commercial volume, supporting Lilly's $27.7 billion H1 GLP-1 revenue base.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYPBM formulary access driving commercial oral GLP-1 volume adoptionUp1-3mGLP-1 sales hit $27.7B in H1 2026 and oral pill Foundayo gained coverage across major PBMs.
    NVOmetabolic market share competition in oral obesity formulationsWatch1-3mNovo Nordisk competes directly with Eli Lilly in GLP-1 and oral obesity drug markets.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    NVOWatch43.24 2026-09-18-7.96%-10.27%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month